US drug major Wyeth's osteoporosis drug candidate bazedoxifene received a third "approvable" letter in the same week that a second drug candidate, Relistor (methylnaltrexone bromide) injection, missed its primary endpoint in a late-stage post-operative ileus study.
The Food and Drug Administration issued an approvable letter on May 21 for Wyeth's selective estrogen receptor modulator, for the treatment of postmenopausal osteoporosis, requesting information similar to that outlined in its second letter issued in December 2007. This included further analyses concerning the incidence of stroke and venous thrombotic events. The agency also identified specific questions concerning data collection and reporting, and requested additional source documents.
"Today's action is in line with our expectations," said Gary Stiles, chief medical officer of Wyeth Pharmaceuticals. "In our conference with the agency earlier this year, they stated their desire to convene an advisory committee to review the pending New Drug Applications for both treatment and prevention of postmenopausal osteoporosis," he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze